*
Based on the average weight loss in three 68-week clinical trials of
patients without diabetes who reached and maintained a dose of 2.4
mg/week of GLP-1 treatment, along with a reduced-calorie diet and
increased physical activity. See details. Results may vary based on
starting weight and program adherence. Medication prescriptions are at
the discretion of medical providers and may not be suitable for
everyone. Consult a healthcare professional before starting any weight
loss program. Safety info: GLP-1 medications are used to treat obesity
or overweight individuals (with weight-related problems), along with
diet and exercise. They may have serious side effects, including
possible thyroid tumors. Do not use if you or your family have a history
of a type of thyroid cancer called MTC or MEN 2. + Wegovy® is
FDA-approved for weight loss. Ozempic® is FDA-approved for type 2
diabetes treatment but may be prescribed for weight loss. The
trademarks, service marks, trade names (Wegovy®, Ozempic®), and products
displayed on this Internet site are protected and belong to their
respective owners.